BGG issued patent on AstaZine natural astaxanthin for heart health

Photo © iStockphoto.com

BGG World (Irvine, CA) was issued a patent from the United States Patent and Trademark Office for the use of astaxanthin to support heart function during exercise (US Patent #10,827,775).

The patent is based on results from a clinical trial, sponsored by BGG, with amateur athletes preparing for a half marathon. Subjects supplementing BGG’s AstaZine natural astaxanthin experienced heart rates on average 10% lower during endurance training than the placebo group. 

According to Shawn Talbott, lead researcher of the study, “Subjects were able to perform the same amount of ‘work’ but at lower cardiovascular ‘strain’ after supplementing with astaxanthin.”

Further, lead inventor of the patent and BGG’s global chief scientific officer, Yanmei Li, PhD, said in a press release, “BGG focuses on innovation by dedicating 5% of gross revenue to R&D. As a prime example of this policy, we are one of only a very small handful of astaxanthin producers sponsoring clinical research to validate our product and have published several astaxanthin clinical studies over the last few years. This patent is another example of how BGG supports our customers through our investment in research and constant innovation; we’ve successfully opened up a whole new area of health benefits for our astaxanthin customers to focus on.”